 Kasey Couts
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 25 | 2026 | 759 | 4.070 |
Why?
| | Skin Neoplasms | 8 | 2025 | 850 | 1.610 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2025 | 212 | 1.250 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2025 | 224 | 1.230 |
Why?
| | Mucous Membrane | 3 | 2024 | 128 | 0.960 |
Why?
| | Dasatinib | 1 | 2024 | 57 | 0.820 |
Why?
| | Septins | 1 | 2018 | 43 | 0.540 |
Why?
| | Lysophospholipids | 2 | 2026 | 78 | 0.420 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2026 | 917 | 0.380 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2024 | 76 | 0.370 |
Why?
| | Melanocytes | 1 | 2012 | 65 | 0.360 |
Why?
| | Cell Line, Tumor | 9 | 2026 | 3537 | 0.350 |
Why?
| | MicroRNAs | 2 | 2014 | 689 | 0.300 |
Why?
| | Uveal Neoplasms | 2 | 2026 | 16 | 0.290 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2207 | 0.240 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2026 | 53 | 0.240 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 40 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 35 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2018 | 929 | 0.220 |
Why?
| | alpha 1-Antitrypsin | 1 | 2026 | 104 | 0.210 |
Why?
| | Mice | 10 | 2026 | 18338 | 0.210 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 30 | 0.210 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2024 | 39 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 620 | 0.210 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 505 | 0.200 |
Why?
| | Immunity, Cellular | 1 | 2026 | 273 | 0.200 |
Why?
| | Anus Neoplasms | 1 | 2024 | 32 | 0.200 |
Why?
| | Azepines | 1 | 2024 | 106 | 0.200 |
Why?
| | MAP Kinase Signaling System | 3 | 2012 | 306 | 0.200 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 38 | 0.200 |
Why?
| | Intestine, Small | 1 | 2024 | 167 | 0.200 |
Why?
| | Signal Transduction | 6 | 2026 | 5202 | 0.190 |
Why?
| | Mutation | 5 | 2022 | 4093 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 272 | 0.190 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.190 |
Why?
| | Humans | 31 | 2026 | 145491 | 0.190 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1439 | 0.190 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 159 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 257 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 102 | 0.180 |
Why?
| | HLA-DR Antigens | 1 | 2022 | 220 | 0.180 |
Why?
| | Genomics | 2 | 2024 | 834 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 168 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 439 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2022 | 201 | 0.160 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.150 |
Why?
| | Mice, Nude | 2 | 2020 | 678 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 779 | 0.150 |
Why?
| | Immunity, Innate | 1 | 2025 | 846 | 0.150 |
Why?
| | Animals | 10 | 2026 | 38141 | 0.150 |
Why?
| | Middle Aged | 8 | 2025 | 36176 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2020 | 122 | 0.150 |
Why?
| | Female | 12 | 2026 | 78763 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 990 | 0.140 |
Why?
| | GTP Phosphohydrolases | 1 | 2018 | 93 | 0.140 |
Why?
| | Neoplasms | 2 | 2024 | 2897 | 0.140 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2009 | 174 | 0.130 |
Why?
| | Proteomics | 3 | 2014 | 1191 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 197 | 0.130 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1769 | 0.130 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 6 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 72 | 0.120 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 66 | 0.120 |
Why?
| | Phosphoproteins | 2 | 2017 | 339 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 41 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 980 | 0.120 |
Why?
| | Male | 10 | 2025 | 72817 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.120 |
Why?
| | Sulfonamides | 1 | 2020 | 581 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 396 | 0.120 |
Why?
| | Exome | 1 | 2017 | 227 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 443 | 0.120 |
Why?
| | Microbiota | 1 | 2023 | 784 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2023 | 774 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1321 | 0.110 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2026 | 40 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 693 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 431 | 0.100 |
Why?
| | Cell Cycle | 1 | 2006 | 595 | 0.100 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2012 | 28 | 0.090 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2012 | 70 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 883 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 473 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 751 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 737 | 0.080 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 632 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2411 | 0.080 |
Why?
| | Aged | 4 | 2024 | 26125 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 238 | 0.070 |
Why?
| | Adult | 5 | 2025 | 40707 | 0.070 |
Why?
| | Immunotherapy | 2 | 2024 | 667 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2026 | 3125 | 0.070 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 372 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2009 | 320 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3917 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 590 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 59 | 0.060 |
Why?
| | Cell Movement | 2 | 2025 | 961 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 42 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2012 | 2499 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2025 | 125 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 129 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2026 | 384 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2024 | 1487 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 553 | 0.050 |
Why?
| | Haplotypes | 1 | 2025 | 498 | 0.050 |
Why?
| | New York | 1 | 2023 | 127 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 208 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 24 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 153 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 264 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 691 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4323 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2022 | 3619 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 125 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2024 | 418 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 441 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8326 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2026 | 2189 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1269 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 673 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 96 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 384 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2093 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 881 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 893 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1468 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 137 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 146 | 0.040 |
Why?
| | Phosphorylation | 2 | 2009 | 1707 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 36 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2024 | 699 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 379 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2026 | 2045 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 185 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 536 | 0.030 |
Why?
| | Octamer Transcription Factors | 1 | 2006 | 3 | 0.030 |
Why?
| | Peptide Elongation Factor 2 | 1 | 2006 | 5 | 0.030 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2006 | 6 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 994 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1374 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 110 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1996 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 141 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 156 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2026 | 5989 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2006 | 762 | 0.030 |
Why?
| | HeLa Cells | 1 | 2006 | 633 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 17269 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2014 | 83 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2014 | 150 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5992 | 0.030 |
Why?
| | Blood Glucose | 1 | 2024 | 2330 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1965 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2137 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 461 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2910 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1605 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11831 | 0.020 |
Why?
| | Group II Chaperonins | 1 | 2009 | 2 | 0.020 |
Why?
| | Melanoma, Experimental | 1 | 2009 | 109 | 0.020 |
Why?
| | Spheroids, Cellular | 1 | 2009 | 74 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4283 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14192 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 396 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2009 | 182 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5426 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 436 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1855 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3424 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 2820 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 744 | 0.010 |
Why?
| | Adolescent | 1 | 2025 | 22485 | 0.010 |
Why?
| | Child | 1 | 2025 | 22680 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 7171 | 0.010 |
Why?
|
|
Couts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|